IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性

doi:10.11904/j.issn.1002-3070.2024.05.007

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (5): 323-329.doi: 10.11904/j.issn.1002-3070.2024.05.007

IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性

杨闽叶¹, 鲜童丞¹, 刘景建², 别俊³, 王杰¹, 罗义¹

1.川北医学院附属南充市中心医院乳甲血管外科(南充 637000);
2.川北医学院基础医学与法医学研究所;
3.川北医学院附属南充市中心医院肿瘤科

收稿日期:2023-12-30 修回日期:2024-08-22 出版日期:2024-10-28 发布日期:2025-01-09
通讯作者: 罗义,E-mail:443713587@qq.com
作者简介:杨闽叶,女,(1996-),硕士,住院医师,从事乳腺癌基础与临床研究。
基金资助:
四川省科技计划项目(编号:2023YFS0473);川北医学院2023年度校级科研发展计划项目(编号:CBY23-QNA57)

The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics

YANG Minye¹, XIAN Tongcheng¹, LIU Jingjian², BIE Jun³, WANG Jie¹, LUO Yi¹

1. Department of Breast,Thyroid and Vascular Surgery,Affiliated Nanchong Central Hospital of North Sichuan Medical College,Nanchong 637000,China;
2. Department of Oncology,Affiliated Nanchong Central Hospital of North Sichuan Medical College;
3. Institute of Basic Medicine and Forensic Medicine,North Sichuan Medical College

Received:2023-12-30 Revised:2024-08-22 Online:2024-10-28 Published:2025-01-09

摘要/Abstract

摘要： 目的探讨白介素-23(Interleukin-23,IL-23)在乳腺癌组织中的表达及其与临床病理特征的相关性。方法收集2020年1月—2020年12月南充市中心医院确诊的100例乳腺癌患者的癌组织及癌旁组织,采用免疫组化法及Real-time PCR法测定两组组织中IL-23蛋白及mRNA表达,比较乳腺癌组织与癌旁组织中IL-23蛋白和mRNA表达水平并分析IL-23表达与乳腺癌临床病理特征的关系。结果 IL-23蛋白主要在乳腺癌细胞的胞膜和胞浆中表达。乳腺癌组织中IL-23蛋白及mRNA的表达水平均高于癌旁组织(P＜0.001),其表达与乳腺癌组织学分级、T分期、临床分期及Ki-67均呈正相关,与ER、PR表达均呈负相关(P＜0.05),与乳腺癌神经脉管浸润、年龄、HER-2表达无关(P＞0.05)。结论 IL-23可能参与乳腺癌的进展过程,其表达和ER、PR、Ki-67等预后指标密切相关,提示其表达可能和预后有关,但还需进一步实验验证。

关键词: 白介素-23, 雌激素受体, 孕激素受体, 乳腺癌, 淋巴结转移

Abstract: Objective The aim of this study was to investigate the expression of IL-23(IL-23)in breast cancer and its correlation with clinicopathological characteristics. Methods The tumor tissues and adjacent tissues of 100 patients with breast cancer diagnosed in Nanchong Central Hospital from January 2020 to December 2020 were collected.Immunohistochemistry and Real-Time PCR were used to determine the expression of IL-23 protein and mRNA in the two groups of tissues.The expression of IL-23 protein and mRNA in breast cancer tissues and adjacent tissues were compared,and the relationship between IL-23 expression and the clinicopathological characteristics of breast cancer was analyzed. Results IL-23 protein was mainly expressed in the membrane and cytoplasm of breast cancer cells.The expression of IL-23 protein and mRNA in breast cancer tissues were higher than those in adjacent tissues(P＜0.001).The expression of IL-23 protein and mRNA was positively correlated with the histological grade,T grade,clinical stage and Ki-67 expression of breast cancer,negatively correlated with the expression of ER and PR(P＜0.05),and was not related to neurovascular invasion,age and HER-2 expression in breast cancer(P＞0.05). Conclusion IL-23 may participate in the progression of breast cancer,and its expression is closely related to ER,PR,Ki-67 and other prognostic indicators,suggesting that its expression may be related to the prognosis,but it needs further experimental verification.

Key words: Interleukin-23, Estrogen receptor, Progesterone receptor, Breast cancer, Lymph node metastasis

中图分类号:

R737.9

杨闽叶, 鲜童丞, 刘景建, 别俊, 王杰, 罗义. IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性[J]. 实用肿瘤学杂志, 2024, 38(5): 323-329.

YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics[J]. Journal of Practical Oncology, 2024, 38(5): 323-329.

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Center,2024,4(1):47-53.
3 Zhu JW,Charkhchi P,Adekunte S,et al.What is known about breast cancer in young women?[J].Cancers(Basel),2023,15(6):1917.
4 Comen EA,Norton L,Massagué J.Breast cancer tumor size,nodal status,and prognosis:biology trumps anatomy[J].J Clin Oncol,2011,29(19):2610-2612.
5 Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
6 Schinocca C,Rizzo C,Fasano S,et al.Role of the IL-23/IL-17 pathway in rheumatic diseases:an overview[J].Front Immunol,2021,12:637829.
7 Liu T,Li S,Ying S,et al.The IL-23/IL-17 pathway in inflammatory skin diseases:from bench to bedside[J].Front Immunol,2020,11:594735.
8 Suzuki H,Ogawa H,Miura K,et al.IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma[J].Oncol Lett,2012,4(2):199-204.
9 Xu X,Yang C,Chen J,et al.Interleukin-23 promotes the migration and invasion of gastric cancer cells by inducing epithelial-to-mesenchymal transition via the STAT3 pathway[J].Biochem Biophys Res Commun,2018,499(2):273-278.
10 Zang M,Li Y,He H,et al.IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection[J].Biochim Biophys Acta Mol Basis Dis,2018,1864(12):3759-3770.
11 Fukuda M,Ehara M,Suzuki S,et al.IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity[J].Int J Oncol,2010,36(6):1355-1365.
12 Pellegrini C,Orlandi A,Costanza G,et al.Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments[J].PLoS One,2017,12(8):e0183415.
13 Gangemi S,Minciullo P,Adamo B,et al.Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients[J].J Cell Biochem,2012,113(6):2122-2125.
14 乳腺癌诊疗指南(2022年版)[J].中国合理用药探索,2022,19(10):1-26.
15 中国临床肿瘤学会乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中华医学会外科学分会乳腺外科学组.中国年轻乳腺癌诊疗专家共识(2022)[J].中华医学杂志,2023,103(6):387-403.
16 林燕,孙强,宋雨等.中国老年乳腺癌诊疗专家共识(2023版)[J].中国研究型医院,2023,10(5):1-8.
17 Giuliano AE,Connolly JL,Edge SB,et al.Breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(4):290-303.
18 王朋敏,王鑫,张晶,等.IL-23/Th17相关细胞因子在基底细胞癌中的表达水平及意义[J].中国皮肤性病学杂志,2020,34(5):530-533.
19 田红岭,侯玉柱,王若雨,等.IL-23生理病理学意义及信号通路[J].免疫学杂志,2014,30(6):555-559.
20 Najm A,McInnes IB.IL-23 orchestrating immune cell activation in arthritis[J].Rheumatology(Oxford),2021,60(Suppl 4):iv4-iv15.
21 Yan J,Smyth MJ,Teng MWL.Interleukin(IL)-12 and IL-23 and their conflicting roles in cancer[J].Cold Spring Harb Perspect Biol,2018,10(7):a028530.
22 Sheng S,Zhang J,Ai J,et al.Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance[J].Mol Med Rep,2018,17(3):4639-4644.
23 Kunc M,Biernat W,Senkus-Konefka E.Estrogen receptor-negative progesterone receptor-positive breast cancer -“Nobody′s land” or just an artifact?[J].Cancer Treat Rev,2018,67:78-87.
24 Karihtala P,Kauppila S,Soini Y,et al.Oxidative stress and counteracting mechanisms in hormone receptor positive,triple-negative and basal-like breast carcinomas[J].BMC Cancer,2011,11:262.
25 Kim SJ,Saeidi S,Cho NC,et al.Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression:Implications for breast cancer progression[J].Cancer Lett,2021,500:147-160.
26 Nawas AF,Mistry R,Narayanan S,et al.IL-1 induces p62/SQSTM1 and autophagy in ERα+/PR+BCa cell lines concomitant with ERα and PR repression,conferring an ERα-/PR-BCa-like phenotype[J].J Cell Biochem,2019,120(2):1477-1491.
27 Jiménez-Garduño AM,Mendoza-Rodríguez MG,Urrutia-Cabrera D,et al.IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells[J].Biochem Biophys Res Commun,2017,490(3):780-785.
28 Schillace RV,Skinner AM,Pommier RF,et al.Estrogen receptor,progesterone receptor,interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations[J].BMC Cancer,2014,14:733.
29 Shao N,Lu Z,Zhang Y,et al.Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway[J].Cancer Lett,2015,364(2):165-172.
30 Frasor J,El-Shennawy L,Stender JD,et al.NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms[J].Mol Cell Endocrinol,2015,418 Pt 3(3):235-239.
31 Yerushalmi R,Woods R,Ravdin PM,et al.Ki67 in breast cancer:prognostic and predictive potential[J].Lancet Oncol,2010,11(2):174-183.
32 Nie W,Yu T,Sang Y,et al.Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment[J].Biochem Biophys Res Commun,2017,482(4):1400-1406.

[1]	庞琬莹, 安静, 刘兆良. TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究[J]. 实用肿瘤学杂志, 2024, 38(6): 402-409.
[2]	张宇晴, 荆晶, 刘兆良, 安静, 安巍巍. MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物[J]. 实用肿瘤学杂志, 2024, 38(5): 313-322.
[3]	刘冬, 张太娟, 党计锋. 炎症反应驱动乳腺癌转移的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 336-341.
[4]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[5]	高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.
[6]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[7]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[8]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[9]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[10]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[11]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[12]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[13]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[14]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[15]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.

IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性

The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价